Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCDPHP ARB Step Therapy Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCDPHPPolicy N/A

    ARB Step Therapy

    Customize your policy alerts

    Sign up for all cdphp policy alerts

    Know when cdphp releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy requirements for selected drugs, including ARB products, bempedoic acid products, fluticasone HFA inhalers, and penicillamine or trientine capsules.

    Policy Summary
    PayerCDPHP
    PolicyARB Step Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202740d
    Next Review DateN/A
    Key ActionVerify the required prerequisite therapy in the prescription profile within the last 365 days before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Step-therapy sections
    365 daysPrescription-profile lookback
    7Accepted generic statins
    1Fluticasone exception

    Drug-Specific Coverage Criteria

    ARB products

    Policy Summary
    PayerCDPHP
    PolicyARB Step Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202740d
    Next Review DateN/A
    Key ActionVerify the required prerequisite therapy in the prescription profile within the last 365 days before requesting coverage.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaProvider Documentation and Step-Therapy ActionsInitial Therapy RequirementsRequired Prerequisite Trials

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ARB products are listed with criteria pending CMS review.

    ARB criteria: Criteria: PENDING CMS REVIEW

    No operational coverage criterion is provided in this section.

    Nexletol or Nexlizet initial therapy

    Coverage requires one of the following prerequisite statin trials.

    Accepted generic statin trial

    • Atorvastatin: Trial of atorvastatin
    • Fluvastatin: Trial of fluvastatin
    • Lovastatin: Trial of lovastatin
    • Pitavastatin: Trial of pitavastatin
    • Pravastatin: Trial of pravastatin
    • Rosuvastatin: Trial of rosuvastatin
    • Simvastatin: Trial of simvastatin

    Fluticasone HFA initial therapy

    Coverage requires Qvar inhaler trial unless the specified clinical exception applies.

    Fluticasone HFA prerequisite or exception

    • Qvar trial: Trial of Qvar inhaler
    • cGvHD-BOS exception: Requested for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

      Prerequisite trial is not required for this indication.

    Penicillamine or trientine capsule initial therapy

    Coverage requires a trial of penicillamine tablets.

    Penicillamine tablet prerequisite: A trial of penicillamine tablets, generic for Depen, is required before coverage of penicillamine capsules or trientine capsules.

    If penicillamine tablets appear in the prescription profile within the last 365 days, additional documentation is not required.

    Provider Documentation and Step-Therapy Actions

    Step Therapy

    Bempedoic Acid Products Require a Generic Statin Prerequisite

    Coverage of Nexletol or Nexlizet requires a trial of ONE listed generic statin before approval.

    • Affected products: Nexletol 180 mg tablet and Nexlizet 180 mg-10 mg tablet.
    • Acceptable generic statins: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
    Step Therapy

    Fluticasone HFA Requires Qvar or a Qualifying Exception

    Coverage of fluticasone HFA requires a trial of Qvar inhaler unless the pulmonary chronic graft-versus-host disease exception applies.

    • Affected product: fluticasone propionate 44 mcg/actuation HFA aerosol inhaler.
    • The prerequisite trial is not required when the drug is requested for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome (cGvHD-BOS) after allogeneic hematopoietic stem cell transplantation (alloHSCT).
    Step Therapy

    Capsules Require a Penicillamine Tablet Prerequisite

    Coverage of penicillamine capsules or trientine capsules requires a trial of penicillamine tablets, the generic for Depen.

    • Affected products: penicillamine 250 mg capsules and trientine 500 mg capsules.
    Documentation Required

    Verify Statin History in the Prescription Profile

    Verify the member’s prescription profile for evidence that one required generic statin was dispensed within the past 365 days. If the prerequisite drug appears in the profile during this lookback period, additional documentation is not required.

    • Review the prescription profile for atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
    Documentation Required

    Verify Qvar History in the Prescription Profile

    Verify the member’s prescription profile for a Qvar inhaler trial within the past 365 days. If Qvar appears in the profile during this lookback period, additional documentation is not required.

    • The prescription-profile verification requirement does not replace the pulmonary cGvHD-BOS after alloHSCT exception, which waives the prerequisite trial.
    Documentation Required

    Verify Penicillamine Tablet History

    Verify the member’s prescription profile for a penicillamine tablet trial within the past 365 days. If the required tablet appears in the profile during this lookback period, additional documentation is not required.

    • The prerequisite is penicillamine tablets, the generic for Depen.
    Denial Risk

    Generic Statin Trial Required

    A Nexletol or Nexlizet request may be denied if the member has not tried at least one of the listed generic statins.

    • Required trial: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
    • A prescription-profile record within the last 365 days satisfies the documentation requirement for the prerequisite trial.
    Denial Risk

    Qvar Trial Required Unless an Exception Applies

    A fluticasone HFA request may be denied unless the member has tried Qvar, unless the request qualifies for the pulmonary chronic graft-versus-host disease exception.

    • Exception: pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome (cGvHD-BOS) after alloHSCT.
    • A Qvar prescription in the profile within the last 365 days satisfies the documentation requirement.
    Denial Risk

    Penicillamine Tablet Trial Required

    A request for penicillamine or trientine capsules may be denied if the member has not tried penicillamine tablets.

    • Required prerequisite: penicillamine tablets, the generic for Depen.
    • A penicillamine tablet prescription in the profile within the last 365 days satisfies the documentation requirement.

    Initial Therapy Requirements

    Nexletol or Nexlizet

    Coverage of Nexletol or Nexlizet requires a trial of one generic statin.

    Generic statin prerequisite: Trial of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.1 statin

    If the required drug appears in the prescription profile within the last 365 days, additional documentation is not required.

    Fluticasone HFA

    Coverage of fluticasone HFA requires a trial of Qvar inhaler unless the specified exception applies.

    Qvar prerequisite or clinical exception: Trial of Qvar inhaler, or use for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

    If Qvar appears in the prescription profile within the last 365 days, additional documentation is not required.

    Penicillamine or trientine capsules

    Coverage of penicillamine capsules or trientine capsules requires a trial of penicillamine tablets.

    Penicillamine tablet prerequisite: Trial of penicillamine tablets, generic for Depen.

    If penicillamine tablets appear in the prescription profile within the last 365 days, additional documentation is not required.

    Required Prerequisite Trials

    StepPrerequisiteDocumentation
    1Trial of one generic statin: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.If the required drug appears in the prescription profile within the last 365 days, additional documentation is not required.
    StepPrerequisiteException
    1Trial of Qvar inhaler.The prerequisite trial is not required when fluticasone HFA is requested for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    StepPrerequisiteDocumentation
    1Trial of penicillamine tablets, generic for Depen.If penicillamine tablets appear in the prescription profile within the last 365 days, additional documentation is not required.